Category Archives: Business and Investments

Latest From Business and Investments

ISO: Biotech Humanitarian

We are looking for biotech humanitarians for our annual Biotech Humanitarian Award. The award recognizes an everyday hero who has helped to heal, fuel or feed the planet through their work in biotechnology. Know someone that you feel should be recognized for their good works? Nominate someone at www.iambiotech.org/award through January 31, 2010. 2009 Biotech Humanitarian Dr. Jay Keasling, was nominated by a colleague at the University of California at Berkley. Just think, you or your Read More >

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: , , ,

Risk/Reward Favored Small & Micro Caps in 2009

For US biotechs in 2009, the smaller the company’s market capitalization, the higher the return…

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: ,

2009 – A Big Year for the BTK

The Amex Biotech Index, the BTK, outpaced its peer, the Nasdaq Biotech Index, by 29% and was 22% above the SP500.   Most of this can be attributed to 3rd quarter performance when Human Genome Sciences (HGSI) released P3 data for their antibody drug for Lupus. HGSI gained 555% in 3Q09, and the impact on the 20 company BTK can be seen in the lower bar chart. * *It should be noted that both major Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , ,

Small Biotechs Spending Less

The median and mean operational cash spending for small public US biotechs (less than 250 employees) is down 37% and 42% respectively, since the 1st Quarter of 2008. Company cut backs have shown up in the lay-off numbers as well as in the number of drug development projects put on hold. These quarterly numbers give a sense of the direction. For a look at the annual data, here is how spending breaks down for the Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , ,

1 in 4 Biotechs Above 100% – Waterfall Chart YTD

Year to date,  27% of biotech stocks have doubled in price. 65% are in positive territory in 2009, a strong contrast to the YTD data last year:

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , , ,